

Title (en)  
5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS

Title (de)  
HEMMER DES 5-LIPOXYGENASE AKTIVIERENDEN PROTEINS (FLAP)

Title (fr)  
INHIBITEURS DE LA PROTEINE D'ACTIVATION DE LA 5-LIPOXYGENASE (FLAP)

Publication  
**EP 1942896 A4 20100602 (EN)**

Application  
**EP 06827508 A 20061103**

Priority

- US 2006043095 W 20061103
- US 73403005 P 20051104
- US 74717406 P 20060512
- US 82334406 P 20060823

Abstract (en)

[origin: GB2431927A] Compounds of formula (G) modulate the activity of 5-lipoxygenase-activating protein (FLAP). <EMI ID=1.1 HE=46 WI=71 LX=637 LY=796 TI=CF> Such FLAP modulators, alone and in combination with other compounds, may be used for treating inflammation and respiratory, cardiovascular and other leukotriene-dependent or leukotriene mediated conditions or diseases. In formula (G): <DL TSIZE=4> <DT>Z<DD>is -[C(R<1>)2]m-[C(R<2>)2]n-[C(R<2>)2]n-[C(R<1>)2]m-O-[C(R<1>)2]m-[C(R<2>)2]n-[C(R<2>)2]n-O-[C(R<1>)2]n- or -[C(R<1>)2]n-O-[C(R<2>)2]n- <DT>R<1><DD>is H, CF3, alkyl or two R<1>s are oxo <DT>R<2><DD>is H, CF3, alkyl, OH, OMe or two R<2>s are oxo <DT>Y<DD>is H, aryl or heteroaryl <DT>R<5><DD>is H, halogen, alkyl or alkoxy <DT>R<6><DD>is H or a group as defined herein <DT>R<7> <DD>is an optionally substituted alkyl of formula -L3-X-L4-G1 as defined herein <DT>R<12><DD>is H or alkyl <DT>R<11><DD>is a substituent of formula -L7-L10-G6 or -L7-L10-W-G7 as defined herein provided that it comprises either <SL> <LI>(i) a heteroaryl ring (system) or <LI>(ii) both an aromatic ring (system) and a heterocyclic ring (system) and </SL> </DL> wherein ""alkyl may be cyclic and optionally unsaturated (including aromatic) ""cycloalkyl may be optionally unsaturated (including aromatic) and ""various groups are optionally substituted as defined herein Other indoles of formula (G-I) and (G-II) (as defined herein) are also disclosed.

IPC 8 full level  
**A61K 31/415** (2006.01); **C07D 209/00** (2006.01); **C07D 403/10** (2006.01); **C07D 471/04** (2006.01)

CPC (source: EP GB KR US)

**A61K 31/427** (2013.01 - GB KR); **A61K 31/428** (2013.01 - GB); **A61K 31/4439** (2013.01 - GB); **A61K 31/444** (2013.01 - GB); **A61K 31/4709** (2013.01 - GB); **A61K 31/475** (2013.01 - GB); **A61K 31/497** (2013.01 - GB); **A61K 31/501** (2013.01 - GB KR); **A61K 31/506** (2013.01 - GB); **A61P 1/00** (2017.12 - EP); **A61P 1/04** (2017.12 - EP); **A61P 1/06** (2017.12 - EP); **A61P 3/10** (2017.12 - EP); **A61P 5/50** (2017.12 - EP); **A61P 7/02** (2017.12 - EP); **A61P 9/00** (2017.12 - EP); **A61P 9/02** (2017.12 - EP); **A61P 9/04** (2017.12 - EP); **A61P 9/08** (2017.12 - EP); **A61P 9/10** (2017.12 - EP); **A61P 9/12** (2017.12 - EP); **A61P 9/14** (2017.12 - EP); **A61P 11/00** (2017.12 - EP); **A61P 11/02** (2017.12 - EP); **A61P 11/04** (2017.12 - EP); **A61P 11/06** (2017.12 - EP); **A61P 11/08** (2017.12 - EP); **A61P 13/12** (2017.12 - EP); **A61P 17/00** (2017.12 - EP); **A61P 17/02** (2017.12 - EP); **A61P 17/06** (2017.12 - EP); **A61P 19/02** (2017.12 - EP); **A61P 19/08** (2017.12 - EP); **A61P 19/10** (2017.12 - EP); **A61P 25/02** (2017.12 - EP); **A61P 25/04** (2017.12 - EP); **A61P 25/06** (2017.12 - EP); **A61P 25/16** (2017.12 - EP); **A61P 25/28** (2017.12 - EP); **A61P 27/00** (2017.12 - EP); **A61P 27/02** (2017.12 - EP); **A61P 27/14** (2017.12 - EP); **A61P 29/00** (2017.12 - EP); **A61P 35/00** (2017.12 - EP); **A61P 35/02** (2017.12 - EP); **A61P 35/04** (2017.12 - EP); **A61P 37/06** (2017.12 - EP); **A61P 37/08** (2017.12 - EP); **A61P 39/00** (2017.12 - EP); **A61P 39/02** (2017.12 - EP); **A61P 43/00** (2017.12 - EP); **C07D 401/06** (2013.01 - EP GB US); **C07D 401/10** (2013.01 - EP GB US); **C07D 401/14** (2013.01 - EP GB US); **C07D 403/02** (2013.01 - KR); **C07D 403/14** (2013.01 - EP GB US); **C07D 405/14** (2013.01 - EP GB US); **C07D 413/14** (2013.01 - EP GB US); **C07D 417/02** (2013.01 - KR); **C07D 417/14** (2013.01 - EP GB US); **C07D 471/04** (2013.01 - EP GB US)

Citation (search report)

- [Y] US 5204344 A 19930420 - PRASIT PETPIBOON [US], et al
- [Y] WO 2004017917 A2 20040304 - MERCK & CO INC [US], et al
- [Y] US 5081138 A 19920114 - GILLARD JOHN W [CA], et al
- [X] FR 2431491 A1 19800215 - DELALANDE SA [FR]
- [X] US 6867209 B1 20050315 - MAVUNKEL BABU J [US], et al
- [Y] MILLER D K ET AL: "Identification and isolation of a membrane protein necessary for leukotriene production", NATURE, NATURE PUBLISHING GROUP, LONDON, GB LNKD- DOI:10.1038/343278A0, vol. 343, 18 January 1990 (1990-01-18), pages 278 - 281, XP003015233, ISSN: 0028-0836
- See references of WO 2007056220A2

Citation (examination)

- YOUNG R N: "Inhibitors of 5-lipoxygenase: a therapeutic potential yet to be fully realized?", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, FR, vol. 34, no. 9, 1 September 1999 (1999-09-01), pages 671 - 685, XP004202944, ISSN: 0223-5234, DOI: 10.1016/S0223-5234(99)00225-1
- STOCK N ET AL: "5-Lipoxygenase-activating protein inhibitors. Part 2: 3-{5-((S)-1-Acetyl-2,3-dihydro-1H-indol-2-ylmethoxy)-3-tert-butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-1H-indol-2-yl}-2,2-dimethyl-propionic acid (AM679)A potent FLAP inhibitor", 1 January 2010, BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, PAGE(S) 213 - 217, ISSN: 0960-894X, XP026808808

Designated contracting state (EPC)  
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

Designated extension state (EPC)  
AL BA HR MK RS

DOCDB simple family (publication)  
**GB 0621651 D0 20061206; GB 2431927 A 20070509; GB 2431927 A9 20090225; GB 2431927 B 20100317;** AR 056214 A1 20070926; AR 056215 A1 20070926; AR 057872 A1 20071226; AU 2006311796 A1 20070518; AU 2006311804 A1 20070518; BR P10618047 A2 20110816; CA 2628233 A1 20070518; CA 2628467 A1 20070518; CR 9949 A 20090723; EA 200801164 A2 20081030; EA 200801164 A3 20090227; EP 1942896 A2 20080716; EP 1942896 A4 20100602; EP 1943266 A2 20080716; EP 1943266 A4 20100602; IL 190872 A0 20081103; JP 2009514886 A 20090409; JP 2009514959 A 20090409; JP 5320590 B2 20131023; KR 20080066989 A 20080717; MA 29932 B1 20081103; NO 20081839 L 20080703; SG 165387 A1 20101028; TW 200804276 A 20080116; TW 200804277 A 20080116; TW 200804334 A 20080116;

TW 201402562 A 20140116; US 2009018170 A1 20090115; US 2009221574 A1 20090903; US 2011034514 A1 20110210;  
US 7834037 B2 20101116; US 8841295 B2 20140923; WO 2007056220 A2 20070518; WO 2007056220 A3 20090430;  
WO 2007056228 A2 20070518; WO 2007056228 A3 20071101

DOCDB simple family (application)

**GB 0621651 A 20061031**; AR P060104837 A 20061103; AR P060104838 A 20061103; AR P060104861 A 20061106;  
AU 2006311796 A 20061103; AU 2006311804 A 20061103; BR PI0618047 A 20061103; CA 2628233 A 20061103; CA 2628467 A 20061103;  
CR 9949 A 20080430; EA 200801164 A 20061103; EP 06827508 A 20061103; EP 06836946 A 20061103; IL 19087208 A 20080415;  
JP 2008539090 A 20061103; JP 2008540097 A 20061103; KR 20087013546 A 20080604; MA 30901 A 20080505; NO 20081839 A 20080416;  
SG 2010067122 A 20061103; TW 102131359 A 20061103; TW 95140834 A 20061103; TW 95140880 A 20061103; TW 95141065 A 20061106;  
US 2006043095 W 20061103; US 2006043108 W 20061103; US 8970606 A 20061103; US 90632510 A 20101018; US 92584107 A 20071027